AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 09:20:15 2024-03-04 am EST 5-day change 1st Jan Change
10,015 GBX -0.64% Intraday chart for AstraZeneca PLC -2.28% -5.47%
This Alpha-Value article, the European leader in independent research, is only available to subscribers .
Alpha-Value is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
AstraZeneca Says EMA Accepts its Potential Lung, Breast Cancer Drug Treatment Applications for Review MT
AstraZeneca: EMA validates Dato-DXd for two cancers CF
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment AN
Repeat & Correct : AstraZeneca Advances Cancer Drug After EMA Accepts Marketing Applications DJ
AstraZeneca Gets EU Marketing Approvals for Cancer Drug DJ
AstraZeneca, Daiichi Sankyo Complete Marketing Application in Europe for Cancer Treatment MT
Judge Throws Out AstraZeneca's Challenge to IRA Drug-Price Provisions DJ
US judge upholds Medicare drug price negotiation program RE
Second judge upholds Medicare drug price negotiation program RE
GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 million pounds in 2023 RE
FibroGen regains rights to anemia drug from AstraZeneca RE
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea CI
AstraZeneca Says EU Regulator's Committee Recommending Marketing Authorization for Voydeya MT
Astrazeneca plc Announces Voydeya Recommends for Approval in the Eu by Chmp as Add-On Treatment to Ravulizumab or Eculizumab CI
Rising metal prices and homebuilders investigation weigh on London shares Our Logo
AstraZeneca: CHMP delivers a positive opinion on HPN CF
AstraZeneca's Voydeya treatment recommended for EU approval AN
AstraZeneca's Rare Blood Disease Drug Wins EMA Committee's Positive Opinion MT
AstraZeneca Says Fasenra Shows Supports Corticosteroids Remission in Eosinophilic Granulomatosis with Polyangiitis MT
FTSE 100 Closes Up 0.3%, Standard Chartered Outperforms on Buyback DJ
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS... Our Logo
Silence Therapeutics Achieves Milestone Payment Under AstraZeneca Collaboration MT
EMA Says CHMP Completed Review Of Ibuprofen NVT RE
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher MT
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track" AN
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
127.4 USD
Average target price
161.7 USD
Spread / Average Target
+26.98%
Consensus
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.
  4. News AstraZeneca PLC
  5. AstraZeneca : Moderating our over-optimistic expectations for improved profitability
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW